Class Action Lawsuit Targets ImmunityBio Over Alleged Anktiva Misstatements
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against ImmunityBio, Inc. ($INMB) and Regencell Bioscience Holdings Limited, alleging that the companies made materially false and misleading statements regarding the capabilities of Anktiva, a key therapeutic candidate. The lawsuit specifically names Patrick Soon-Shiong, ImmunityBio's principal figure, as a defendant, claiming he overstated Anktiva's potential during a critical period when investor confidence was particularly vulnerable. Investors who purchased ImmunityBio stock during the Class Period—spanning January 19 through March 24, 2026—may be eligible to recover losses as part of the litigation.
The timing of this action comes as biotech companies face heightened scrutiny over clinical trial disclosures and therapeutic claims. The lawsuit represents a significant challenge to the company's public statements during a period when market valuations for biotech firms are heavily dependent on the perceived potential of their drug pipelines. For shareholders who experienced substantial losses during this window, the legal proceeding offers a potential avenue for recovery, though the outcome remains uncertain.
Key Details of the Litigation
The class action lawsuit centers on allegations that ImmunityBio and Regencell Bioscience issued statements that misrepresented or omitted material facts about Anktiva's therapeutic capabilities and the company's overall business prospects. According to the complaint, these false and misleading statements were made during the Class Period of January 19 to March 24, 2026, a timeframe that would have been critical for investor decision-making.
Key aspects of the case include:
- Named defendant: Patrick Soon-Shiong, central figure in the company's leadership
- Class Period: January 19, 2026 – March 24, 2026 (approximately two months)
- Lead Plaintiff Deadline: May 26, 2026—investors must act before this date to apply for lead plaintiff status
- Affected security: Common stock of ImmunityBio, Inc. ($INMB)
- Law firm: Bragar Eagel & Squire, P.C., which specializes in securities litigation
Investors who wish to participate in the class action have until the May 26, 2026, deadline to submit applications requesting to be appointed as lead plaintiff. The lead plaintiff role typically involves working closely with counsel and potentially testifying, though it provides greater input into the litigation strategy.
Market Context: Biotech Scrutiny and Disclosure Standards
The ImmunityBio lawsuit reflects broader tensions in the biotechnology sector regarding clinical trial transparency and therapeutic claims. Biotech companies operating in early-stage drug development face constant pressure to demonstrate progress to investors, yet must navigate strict regulatory guidelines from the FDA and other authorities about what claims can be made publicly.
The biopharmaceutical landscape has seen intensified regulatory and investor scrutiny in recent years, particularly following high-profile cases where companies overstated clinical efficacy or downplayed safety concerns. This environment means that:
- Clinical trial disclosures are subject to heightened examination by the SEC and private litigators
- Investor confidence in biotech firms increasingly depends on verified, conservative claims about drug candidates
- Liability exposure for executives and boards has expanded significantly
- Institutional investors now conduct deeper due diligence on biotech claims before committing capital
Anktiva, as the focal point of this litigation, represents the type of asset-in-development that drives biotech valuations. If the company made overstated claims about its capabilities during the Class Period, it would have directly influenced stock prices and investor decision-making during a presumably volatile window for the company's stock.
Investor Implications and Recovery Options
For ImmunityBio shareholders who suffered losses, the lawsuit presents a potential mechanism for recovery, though class action settlements vary widely in terms of compensation amounts. The existence of the lawsuit may also pressure the company toward settlement discussions to avoid prolonged litigation costs and reputational damage.
Important considerations for affected investors:
- Eligibility: Shareholders must have purchased ImmunityBio stock during the Class Period to qualify
- Documentation: Investors should retain all purchase confirmations and trading records
- Deadline: The May 26, 2026 lead plaintiff deadline is a hard cutoff for those seeking to direct the litigation
- Recovery timing: Class action settlements typically take 1-3 years to finalize and distribute to claimants
- Potential outcomes: Settlement amounts depend on various factors including evidence strength, damages calculations, and defendants' resources
For the broader market, the lawsuit sends a cautionary signal to other biotech firms about the importance of precise, substantiated claims regarding drug candidates. Companies that aggressively market therapeutic potential without sufficient clinical evidence now face material legal and financial risk. This may lead to more conservative guidance from biotech management teams and potentially slower stock appreciation for early-stage firms, as investors demand higher evidence thresholds before valuing companies on pipeline potential.
The lawsuit also underscores the competitive liability landscape in securities litigation. Bragar Eagel & Squire actively monitors biotech disclosures for potential violations, and other law firms similarly scan sector filings for alleged misstatements, creating a more litigious environment for company executives and boards.
Looking Forward
As the litigation progresses toward the May 26, 2026, lead plaintiff deadline, ImmunityBio investors should carefully review the complaint's allegations and assess whether they meet eligibility criteria for the class action. The outcome of this case could have implications not only for ImmunityBio ($INMB) shareholders but also for how the broader biotech industry communicates about experimental therapies.
The lawsuit serves as a reminder that in the biotech sector, the gap between marketing narrative and clinical reality carries steep legal consequences. Investors in early-stage drug development companies should maintain heightened scrutiny of claims made in press releases and SEC filings, while companies must ensure that all public statements about therapeutic candidates are supported by robust evidence and appropriately caveated with risk disclosures.